VEGFA and neoplasm: Mazzocca and collaborators reported that pharmacological inhibition of the TGF-β signaling pathway with the TβRI kinase inhibitor LY2109761 impairs tumor angiogenesis by both inhibiting SMAD-dependent VEGF production in HCC cells and hampering the crosstalk between tumor cells and microenvironment, thus inhibiting migration of endothelial cells [94].